Blontuvetmab Biosimilar - Research Grade

Human

MS4A1

>1mg/ml

IgG2 - kappa-lambda

CHO Cells

Bulk Anti-Human CD20 (2H7) Antibody (ICH1012), Rituximab Biosimilar - Research Grade (ICH4011), Obinutuzumab Biosimilar - Research Grade (ICH4026), Ofatumumab Biosimilar - Research Grade (ICH4027), Veltuzumab Biosimilar - Research Grade (ICH5099), Ublituximab Biosimilar - Research Grade (ICH5297), Ibritumomab Biosimilar - Research Grade (ICH5310), Ocrelizumab Biosimilar - Research Grade (ICH5314), Divozilimab Biosimilar - Research Grade (ICH5483), Epitumomab Biosimilar - Research Grade (ICH5530), Ocaratuzumab Biosimilar - Research Grade (ICH5721), Ripertamab Biosimilar - Research Grade (ICH5826), Tositumomab Biosimilar - Research Grade (ICH5937), Zuberitamab Biosimilar - Research Grade (ICH6012)

https://www.imgt.org/mAb-DB/

ICH3002

P11836

Blue ice

This product is a research-grade biosimilar of blontuvetmab, supplied as an unconjugated, non-therapeutic analog intended for research use only. It is built around the CD20 (MS4A1) target rather than being defined by a hybridoma clone, and is manufactured to in-vivo research standards: low endotoxin (research grade <1 EU/mg, ultra-low <0.5 EU/mg) and available at bulk mg-to-gram scale for functional and comparability studies. Blontuvetmab itself is a caninized anti-CD20 monoclonal antibody originally developed for B-cell malignancies, so investigators should confirm the reactive-species intent for their application before use. Because it reproduces the binding characteristics of the originator without any therapeutic labeling, this reagent is well suited to in-vitro and functional work such as CD20 binding assays, epitope and comparability testing, flow-cytometry staining of B cells, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) assays, and as an isotype-matched binding control. It is not a clinical drug and must not be used diagnostically or therapeutically. Note that the target/species metadata on this card should be verified against the intended CD20 ortholog (see flag). CD20, encoded by MS4A1 (membrane-spanning 4-domains subfamily A member 1), is a four-transmembrane phosphoprotein expressed on the surface of B lymphocytes from the late pre-B stage through mature B cells, but absent on pro-B cells and terminally differentiated plasma cells. It is not shed or internalised appreciably and is not present in soluble form, which makes it a durable, cell-restricted surface marker. CD20 organises within the plasma membrane as a store-operated calcium channel component and clusters into lipid rafts, contributing to B-cell activation, proliferation, and calcium flux. Its restricted expression and stable surface localisation underpin its long-standing use as an anti-CD20 antibody target for B-cell depletion in oncology and autoimmunity. CD20 is well conserved across mammals; anti-CD20 antibodies are frequently species- or ortholog-specific, so the exact CD20 ortholog recognised must be confirmed for any given reagent.

B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, B-lymphocyte antigen CD20, CD20

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks